Agenus (NASDAQ:AGEN) Releases Earnings Results, Misses Expectations By $1.08 EPS

Agenus (NASDAQ:AGEN) released its quarterly earnings results on Monday. The biotechnology company reported $1.02 earnings per share for the quarter, missing the consensus estimate of $2.10 by ($1.08), Zacks reports. Agenus had a negative return on equity of 7.65% and a negative net margin of 2.67%.

Agenus Price Performance

Shares of Agenus stock traded down $0.56 during trading on Monday, hitting $3.26. 2,002,836 shares of the company’s stock traded hands, compared to its average volume of 782,172. Agenus has a twelve month low of $2.71 and a twelve month high of $7.34. The company has a market cap of $125.18 million, a PE ratio of -7.09 and a beta of 1.60. The firm’s fifty day moving average price is $3.71 and its 200 day moving average price is $3.68.

Institutional Trading of Agenus

A number of hedge funds have recently modified their holdings of AGEN. EP Wealth Advisors LLC bought a new position in shares of Agenus during the 4th quarter valued at approximately $31,000. Jump Financial LLC acquired a new stake in shares of Agenus during the second quarter worth about $55,000. Squarepoint Ops LLC purchased a new stake in shares of Agenus in the third quarter valued at approximately $54,000. Sherbrooke Park Advisers LLC purchased a new stake in Agenus in the 3rd quarter valued at $64,000. Finally, Quadrature Capital Ltd acquired a new position in shares of Agenus in the 4th quarter valued at $54,000. Institutional investors own 61.46% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on AGEN. Zacks Research upgraded Agenus from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 2nd. Wall Street Zen upgraded Agenus from a “hold” rating to a “buy” rating in a research note on Monday, April 6th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $14.50.

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.